Export financials
Applied Molecular Transport (AMTI)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Applied Molecular Transport Financial Ratios 2022-2011 | AMTI
Annual Financial Ratios Applied Molecular Transport
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
-0.2 | -2.5 | -16.8 | - | - | - | - | - | - | - | - | - |
EPS |
-3.2 | -2.7 | -2.9 | -3.8 | - | - | - | - | - | - | - | - |
EV (Enterprise Value) |
7.6 M | 138 M | 1.12 B | -8.11 M | 47.1 M | - | - | - | - | - | - | - |
EBITDA per Share |
-3.2 | -2.59 | -2.83 | -3.75 | - | - | - | - | - | - | - | - |
EV/EBITDA |
-0.1 | -1.4 | -17.3 | 0.3 | - | - | - | - | - | - | - | - |
PEG |
- | - | 0.13 | - | - | - | - | - | - | - | - | - |
P/B |
0.4 | 1.5 | 8.5 | - | - | - | - | - | - | - | - | - |
P/CF |
-0.2 | -3.0 | -19.0 | - | - | - | - | - | - | - | - | - |
ROE % |
-207.64 | -61.30 | -50.55 | 39.11 | - | - | - | - | - | - | - | - |
ROA % |
-117.57 | -46.85 | -47.48 | -72.78 | - | - | - | - | - | - | - | - |
ROCE % |
-209.11 | -61.61 | -50.64 | -82.01 | - | - | - | - | - | - | - | - |
Current Ratio |
2.3 | 4.2 | 16.5 | 8.3 | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios Applied Molecular Transport
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.17 | -0.44 | -0.71 | - | -0.65 | -0.93 | -1.1 | - | -0.68 | -0.62 | -0.58 | - | -0.48 | -1.11 | -2.06 | - | -1.07 | -0.99 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA per Share |
-0.16 | -0.43 | -0.71 | - | -0.59 | -0.88 | -1.08 | - | -0.61 | -0.58 | -0.56 | - | -0.47 | -1.08 | -2.05 | - | -1.05 | -0.99 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROE % |
-236.06 | -230.12 | -179.46 | -102.23 | -116.09 | -95.29 | -76.54 | -43.24 | -54.49 | -49.95 | -50.22 | -32.20 | -21.23 | 0.22 | 19.72 | 31.35 | 10.97 | 10.19 | 10.19 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROA % |
-157.85 | -147.60 | -101.59 | -68.07 | -80.62 | -70.93 | -62.71 | -39.28 | -49.92 | -46.27 | -46.66 | -30.47 | -50.88 | -59.21 | -10.92 | - | -20.41 | -18.97 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
ROCE % |
-241.69 | -234.10 | -181.52 | -102.71 | -116.57 | -95.37 | -76.55 | -43.25 | -54.53 | -49.95 | -50.32 | -32.28 | -21.27 | 0.28 | -11.73 | - | 11.02 | 10.27 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Current Ratio |
5.3 | 5.8 | 1.8 | 2.3 | 2.7 | 3.0 | 3.4 | 4.2 | 10.6 | 13.9 | 9.8 | 16.5 | 18.3 | 22.9 | 16.5 | 8.3 | 8.3 | 8.3 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company Applied Molecular Transport, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
Financial Ratios of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Kamada Ltd.
KMDA
|
$ 8.46 | 0.87 % | $ 488 M | ||
|
Kiniksa Pharmaceuticals, Ltd.
KNSA
|
$ 74.61 | 0.03 % | $ 5.54 B | ||
|
Kodiak Sciences
KOD
|
$ 94.8 | 4.04 % | $ 5.04 B | ||
|
Karyopharm Therapeutics
KPTI
|
$ 1.22 | 1.24 % | $ 13.3 K | ||
|
Keros Therapeutics
KROS
|
$ 11.4 | 1.88 % | $ 424 M | ||
|
Krystal Biotech
KRYS
|
$ 332.56 | 0.12 % | $ 9.63 B | ||
|
Kura Oncology
KURA
|
$ 10.71 | 1.3 % | $ 939 M | ||
|
Kymera Therapeutics
KYMR
|
$ 111.79 | 1.16 % | $ 9.45 B | ||
|
Kazia Therapeutics Limited
KZIA
|
$ 9.6 | 1.56 % | $ 146 M | ||
|
Lineage Cell Therapeutics
LCTX
|
$ 0.96 | 0.1 % | $ 221 M | ||
|
Legend Biotech Corporation
LEGN
|
$ 19.89 | 5.69 % | $ 7.33 B | ||
|
MediWound Ltd.
MDWD
|
$ 13.77 | 0.25 % | $ 375 M | ||
|
Ligand Pharmaceuticals Incorporated
LGND
|
$ 312.37 | 0.65 % | $ 6.04 B | ||
|
Longeveron
LGVN
|
$ 2.69 | 0.74 % | $ 47.3 B | ||
|
Eli Lilly and Company
LLY
|
$ 1 157.08 | 0.27 % | $ 1.04 T | ||
|
Lipocine
LPCN
|
$ 2.2 | 1.85 % | $ 12 M | ||
|
Liquidia Corporation
LQDA
|
$ 30.26 | 0.58 % | $ 2.6 B | ||
|
Larimar Therapeutics
LRMR
|
$ 3.2 | 1.75 % | $ 266 M | ||
|
Lantern Pharma
LTRN
|
$ 1.01 | 0.92 % | $ 11 M | ||
|
Lexicon Pharmaceuticals
LXRX
|
$ 1.88 | 0.53 % | $ 683 M | ||
|
Mustang Bio
MBIO
|
$ 0.46 | 0.02 % | $ 2.26 M | ||
|
Moleculin Biotech
MBRX
|
$ 0.5 | 1.84 % | $ 592 K | ||
|
Seres Therapeutics
MCRB
|
$ 3.35 | 0.85 % | $ 29.7 M | ||
|
Madrigal Pharmaceuticals
MDGL
|
$ 503.96 | 0.31 % | $ 11.3 B | ||
|
Mesoblast Limited
MESO
|
$ 14.65 | 2.55 % | $ 17.7 B | ||
|
MacroGenics
MGNX
|
$ 3.86 | 2.39 % | $ 244 M | ||
|
Mirum Pharmaceuticals
MIRM
|
$ 85.48 | 0.46 % | $ 4.29 B | ||
|
Milestone Pharmaceuticals
MIST
|
$ 0.87 | 5.57 % | $ 92.4 M | ||
|
MannKind Corporation
MNKD
|
$ 3.9 | 16.77 % | $ 1.19 B | ||
|
MediciNova
MNOV
|
$ 1.68 | 0.52 % | $ 82.4 M | ||
|
Monopar Therapeutics
MNPR
|
$ 79.67 | 0.17 % | $ 590 M | ||
|
Mereo BioPharma Group plc
MREO
|
$ 0.4 | 7.72 % | $ 319 M | ||
|
Merck & Co.
MRK
|
$ 145.31 | 0.4 % | $ 364 B | ||
|
Marker Therapeutics
MRKR
|
$ 1.07 | 2.36 % | $ 16.4 M | ||
|
Moderna
MRNA
|
$ 192.57 | 3.13 % | $ 74.9 B | ||
|
Maravai LifeSciences Holdings
MRVI
|
$ 7.66 | 0.13 % | $ 1.11 B | ||
|
Matinas BioPharma Holdings
MTNB
|
$ 2.55 | 2.13 % | $ 14 M | ||
|
Neurocrine Biosciences
NBIX
|
$ 141.84 | 2.52 % | $ 14.1 B | ||
|
Nanobiotix S.A.
NBTX
|
$ 31.16 | 0.48 % | $ 1.49 T | ||
|
NuCana plc
NCNA
|
$ 1.35 | 11.57 % | $ 15.2 B | ||
|
Minerva Neurosciences
NERV
|
$ 3.35 | 0.6 % | $ 28.4 M | ||
|
Nektar Therapeutics
NKTR
|
$ 60.55 | 2.2 % | $ 1.02 B | ||
|
Nkarta
NKTX
|
$ 2.62 | 0.19 % | $ 194 M | ||
|
NanoViricides
NNVC
|
$ 1.3 | 0.78 % | $ 26.2 M | ||
|
Nurix Therapeutics
NRIX
|
$ 23.71 | 0.15 % | $ 2.05 B | ||
|
Intellia Therapeutics
NTLA
|
$ 12.06 | 0.25 % | $ 1.31 B | ||
|
Nuvation Bio
NUVB
|
$ 5.6 | 1.07 % | $ 1.91 B | ||
|
Novavax
NVAX
|
$ 10.81 | 0.18 % | $ 1.75 B | ||
|
Novo Nordisk A/S
NVO
|
$ 37.91 | 0.05 % | $ 168 B | ||
|
Novartis AG
NVS
|
$ 142.57 | 0.98 % | $ 276 B |